Portal de Periódicos da CAPES

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis

2016; Elsevier BV; Volume: 303; Linguagem: Inglês

10.1016/j.jneuroim.2016.12.006

1872-8421

Clara Matute‐Blanch, Jordi Río, Luisa María Villar, Luciana Midaglia, Sunny Malhotra, José C. Álvarez‐Cermeño, Ángela Vidal‐Jordana, Xavier Montalbán, Manuel Comabella,

Invertebrate Immune Response Mechanisms

Highlights•The prognostic involvement of CHI3L1 in clinically isolated syndromes is further studied.•Serum CHI3L1 levels are increased by the effect of glatiramer acetate treatment.•Non-responder patients to interferon-beta treatment have increased serum CHI3L1 levels.•Results may suggest a role for CHI3L1 as an interferon-beta treatment response biomarker in RRMS patients.AbstractChitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFNβ) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFNβ-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p=0.014) but unchanged by IFNβ (p=0.830). CHI3L1 was associated with IFNβ response and levels were higher in non-responder group (p=0.020), while GA showed no responder effect (p=0.943). These results suggest a role for CHI3L1 as response biomarker to IFNβ in RRMS patients.Graphical abstract